Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. (DYN) Stock Overview

Explore Dyne Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.

DYN●NASDAQ
HealthcareBiotechnology
$24.28
$0.67(2.69%)
U.S. Market opens in 15h 13m

Dyne Therapeutics, Inc. (DYN)

Meyka AI Score

Z

Key Financials

Market Cap4.5B
P/E Ratio-7.28
EPS (TTM)$-3.22
ROE-0.64%
Fundamental Analysis

AI Price Forecasts

1 Month$24.80
3 Months$35.00
1 Year Target$18.82

DYN Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Dyne Therapeutics, Inc. (NASDAQ: DYN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Dyne Therapeutics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of DYN on the NASDAQ shows an RSI of 39.74, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $18.82 for the NASDAQ listing.

Key metrics behind Dyne Therapeutics, Inc.'s NASDAQ-traded stock include a P/E ratio of -7.28 and a market capitalization of 4.5B. Combined with our AI analysis, these give both institutional and retail investors a clear view of DYN on the NASDAQ.

Price Performance (NASDAQ: DYN)

1-Day Change
-2.69%
5-Day Change
-5.96%
1-Month Change
-6.51%
3-Month Change
31.88%
6-Month Change
59.42%
Year-to-Date (YTD) Change
24.13%
1-Year Change
83.38%
3-Year Change
108.23%
5-Year Change
49.05%
All-Time (Max) Change
1.59%

Contact Information

https://www.dyne-tx.com
781 786 8230
1560 Trapelo Road, Waltham, MA, 02451

Company Facts

2,890 Employees
IPO DateSep 17, 2020
CountryUS
Actively Trading

Frequently Asked Questions